Biotech, Biomaterials and Biomedical: TechConnect Briefs 2015Biotech, Biomaterials and Biomedical TechConnect Briefs 2015

Cancer Nanotechnology Chapter 2

Inhalable Stimuli-Responsive Theranostic Nanoparticles for Cancer in Deep Lung Tissue

Y.H. Abbas
American University in Cairo, Egypt

pp. 90 - 93

Keywords: theranostic nanoparticles, stimuli-resposive nanoparticles, USPIONs, deep lung tissue, cancer, chitosan

Lung cancer is the deadliest solid tumour among all types of cancer. Despite advances in surgery and drug discovery lung cancer remains difficult to treat. This is a result of unavoidable exposure to carcinogens, poor diagnosis, the lack of targeted drug delivery platforms and limitations associated with delivery of drug to deep lung tissue. A non-invasive, patient convenient platform for the targeted delivery of chemotherapeutics to cancer in deeper lung tissue was developed and studied. The formulation consisted of inhalable polyvinylpyrrolidone: maltodextrin (PVP: MD) microparticles (MPs) by spray freeze drying (SFD) encapsulating chitosan (CS) nanoparticles (NPs) loaded with ultra-small superparamagnetic iron oxide nanoparticles (USPIONs) and a chemotherapeutic drug. Ultra-small superparamagnetic nanoparticles (USPIONs) has enhanced drug release by 1.7 fold in response to external magnetic field. CS NPs showed preferential toxicity to tumour cells (A549) in comparison to cultured fibroblasts. The prepared SFD powders had fine particle fraction (FPF≤5 µm) of 40-42 % w/w and mass median aerodynamic diameter (MMAD) of 5-6 µm as determined by the next generation impactor (NGI). The targeted delivery to the lung cancer using the developed formulation seems to be a promising approach.